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ABSTRACT:
A cross talk between the Estrogen Receptor (ESR1) and the Retinoblastoma 
(pRb) pathway has been demonstrated to influence the therapeutic response of 
breast cancer patients but the full mechanism remains poorly understood. Here we 
show that the N-terminal domain of pRb interacts with the CD domain of ESR1 to 
allow for the assembly of intermediate complex chaperone proteins HSP90 and p23. 
We demonstrated that a loss of pRb in human/mouse breast cells decreases the 
expression of the ESR1 protein through the proteasome pathway. Our work reveals a 
novel regulatory mechanism of ESR1 basal turnover and activity and an unanticipated 
relationship with the pRb tumor suppressor.
INTRODUCTION
The histological and molecular classification of 
breast cancer (BC) has drastically helped to characterize 
and treat patients, although the clinical resolution is an 
enigma. A limited number of biomarkers can be used 
to manage BC patients and the estrogen receptor alpha 
(ESR1) is essential for hormonal therapy. Unfortunately, 
almost 30% of BCs are ESR1 negative or acquire 
resistance to hormonal therapy [1,2]. Among specific 
biomarkers that predict the response to therapy or can 
be utilized as new therapeutic targets, pRb is a strong 
candidate [2]. 
The pRb pathway is frequently inactivated in breast 
cancer via a phosphorylation dependent mechanism 
that is driven by the overexpression of cyclin D1 or 
inactivation of the CDK-inhibitor p16ink4a. pRb gene or 
protein loss has also been reported at different frequencies 
[3]. Deletion of Rb1 in mouse mammary stem/bipotent 
progenitor cells induced focal acinar hyperplasia with 
squamous metaplasia that progressed in transplantable 
mammary tumors similar to either luminal-B or TNT 
subtypes [4].
pRb is a multifaceted tumor suppressor protein that 
controls many pathways but has been well-described only 
in its role in  cell cycle control. pRb acts as a repressor 
of the cell cycle by inhibiting the activity of E2F 
transcription factors. Hyper-phosphorylated pRb releases 
E2F transcription factors and allows for the expression of 
genes that mediate entry into the S phase [5]. Emerging 
evidence suggests that pRb has a more complex role in 
cancer initiation and progression [6] and understanding 
which functional biological nodes are altered in pRb 
negative cells is an important question in order to realize 
personalized therapy. 
There is a convincing association between ESR1 
and pRb status. Histological analyses of different breast 
cancer subtypes showed a prevalence of pRb loss in ESR1 
negative tumors [7] with a high frequency of occurrence 
in triple-negative breast cancer subtypes [8]. From a 
therapeutic point of view, a gene expression signature 
of pRb-dysfunction is associated with a relatively poor 
response to endocrine therapy and a better prognosis 
following chemotherapy treatment that is widely utilized 
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in the treatment of ER-negative disease [3,8–10]. 
These data suggest an interaction between the 
pRb pathway and the status of ESR1. In turn, there is 
some evidence in the literature that has driven us to 
hypothesize a direct link between the pRb and ESR1 
protein functionality. pRb is a cofactor for more than 
a hundred proteins [6] including nuclear receptors. 
Rb indirectly enhances the activity of glucocorticoid 
receptors and inhibits the thyroid hormone receptor and 
PPARgamma-dependent transcription [11]. In cancer cells, 
pRb modulates the activity of the AR and ESR1, the two 
principal determinants of hormonal cancer. pRb interacts 
with the androgen receptor in a hormone-independent 
manner (Lu and Danielsen jbc 1998) [12] and can regulate 
its activity via the E2F transcription factor 1 resulting in a 
critical determinant of therapeutic response [13]. Finally, 
pRb interacts in a ligand-dependent manner with the RIZ 
protein, an ESR1 cofactor that can also potentiate SRC-
2 activity on ESR1 signaling [11]. Conversely, the direct 
activity of pRb on ESR1 protein function remains largely 
unknown. 
Here we show that the retinoblastoma protein (pRb) 
is fundamental for ESR1 basal turnover and activity. We 
demonstrated that loss of pRb in human breast cancer 
cells or human/mouse primary mammary cells, but not 
the two related family members p107 and pRb2/p130, 
decreases the expression of the ESR1 protein. Treatment 
with proteasome inhibitors re-establishes the expression of 
ESR1 demonstrating the involvement of the proteasome 
pathway. As confirmed, in RB1 knock down cells, ESR1 
is ubiquitinated to a greater degree than in normal cells. 
Mechanistically, the N-terminal domain of pRb interacts 
with the CD domain of ESR1 to allow for the interaction 
of chaperone proteins and in particular, HSP90 and p23. 
We demonstrated that pRb is important for the formation 
of a chaperone intermediate complex on ESR1.
RESULTS
pRb controls the ESR1 protein level and activity
To test our hypothesis, we have generated MCF7 
(ESR1 positive) cell lines knocked-down for the three 
members of the Retinoblastoma family, pRb, pRb2/p130, 
and p107 (Supplemental Figure 1A) [14,15]. Supplemental 
Figure 1B shows that the loss of pRb family members 
decreased the expression of ESR1 when compared to 
scrambled cells. Among the three members, only pRb is 
involved in this mechanism (Supplemental Figure 1B, 
Figure 1A). The data were obtained in basal conditions in 
the absence of hormones (Charcoal Stripped Serum, CSS). 
We decided to perform all the experiments under these 
conditions unless otherwise indicated. To exclude that the 
mechanism is a characteristic of a single cell line, we have 
down regulated pRb in the T47D ESR1 positive breast 
cancer cell line. The results in T47D cells are comparable 
to those in the MCF7 cells (Figure 1C). In both cell 
lines, the downregulation of ESR1 in RB1 kd cells is 
statistically significant (Figure 1B,D). To confirm the data, 
we have carried out immunofluorescence experiments. 
We observed a reduction in signal intensity of the ESR1 
in MCF7 RB1 kd cells in basal and estradiol-stimulated 
conditions (Figure 1E). To definitively demonstrate that 
the activity of ESR1 was compromised, we have assessed 
the expression of some classical ESR1 target genes [16]. 
We observed that the expression of TFF1 and CTSD are 
down regulated in RB1 kd cells (Supplemental Figure 
1C). Analysis of ESR1 mRNA also showed a reduction in 
RB1 kd cells (Figure 2A). Since the pRb family members 
could bind the ESR1 promoter [17] and the ESR1 protein 
itself regulates its expression [16], we have cloned 
the ESR1 downstream a non-endogenous promoter. A 
Figure 1: RB1 kd MCF7 and T47D cells down regulate 
the ESR1 protein. (A) ESR1 expression in RB1 knocked 
down MCF7 cells. kd1 and kd2 represent two different shRNAs. 
Alpha-tubulin was used as a loading control. (B) Quantification 
of three independent experiments as in (A). y axis represents 
the ratio between the ESR1 and alpha-tubulin proteins and 
normalized to scrambled cells. The RB1 knocked down MCF7 
cells express about 50% less of the ESR1 protein. (C) ESR1 
expression in RB1 knock down T47D cells. (D) Quantification 
of three independent experiments as in (b). The RB1 knock down 
T47D cells express about 56% less of the ESR1 protein. (E) 
MCF7 cells were grown in CSS medium for 3 days (NT) and 
treated with 10-8 estradiol for 45 minutes (E2). Cells were probed 
with an ESR1 antibody (green) and stained with DAPI (blue). 
RB1 kd1 cells express less ESR1 protein.
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western blot analysis indicates that the reduction of ESR1 
relative expression under the non-endogenous promoter is 
comparable with that of endogenous promoter indicating a 
control at the posttranscriptional level (Figure 2B). These 
data indicate that pRb could be a new cofactor of ESR1, 
regulating its protein expression level. 
pRb and ESR1 form a protein complex
To test a possible interaction between pRb and 
ESR1, we have carried out a GST pull down assay with the 
three functional domains of pRb [5,18] and the AB, CD 
and EF domains of the ESR1 protein in MCF7 cells [19]. 
As highlighted in Figure 2C, the pRb N-terminal domain 
interacts with the CD domain of ESR1. To definitively 
demonstrate this interaction, we have performed a co-
immunoprecipitation assay on endogenous proteins. 
Figure 2D shows the in vivo interaction between pRb and 
ESR1.
pRb controls the basal turnover of ESR1 via the 
proteasome pathway
ESR1, as with most of the hormonal receptors, 
is finely regulated at the transcriptional and 
posttranscriptional levels. A key role in protein half-life 
is played by the proteasome pathway [19–21]. Without 
the hormone, the ESR1 is associated with HSP70, HSP40 
and the adapter HIP protein (HSP70-interacting protein) 
to form an early complex. Later on, HSP90 and the 
adapter protein HOP (HSP70/HSP90- organizing protein) 
displace HSP40 and bind the hydrophobic hormone-
binding domain of ESR1 to form an intermediate complex 
[22]. After ATP binding, HSP90 interacts with p23 and 
Cyclophilin 40 (CYP40) to form a mature complex [22]. 
To test if pRb is involved in the ESR1 degradation via 
the proteasome pathway, we have treated the MCF7 cells 
with the proteasome inhibitor MG132 [23]. After 4 hours 
of treatment, RB1 kd cells had the same level of ESR1 as 
scrambled cells, thus rescuing the phenotype observed in 
untreated cells (Figure 3A,B). This finding was confirmed 
Figure 2: In vitro and in vivo interaction between pRb and ESR1 proteins. (A) RB1 kd1 and kd2 MCF7 cell lines have 
about 30% less mRNA levels of ESR1. y axis represents the ratio between ESR1 and GAPDH mRNAs. (B) MCF7 cells were infected 
with a lentivirus that expresses ESR1-V5 under the CMV promoter. RB1 kd1 cells express less endogenous and transfected ESR1 protein, 
demonstrating that the effect is at the posttranslational level. Quantification represents the ratio between the indicated protein and alpha-
tubulin and normalized to scrambled cells. (C) In vitro interaction. ESR1 AB, CD and EF domains were pulleddown with GST-pRb 
N-terminal, Pocket and C-terminal domains in MCF7 cells. There is an interaction between the ESR1CD and pRb N-terminal domains. 
p.RED, pounceau red. (D) In vivo interaction. ESR1 was immunoprecipitated in MCF7 cells and analyzed by western blot with a pRb 
antibody. IgG was used as a negative control.
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in RB1 kd2 cells (Supplemental Figure 2A) and utilizing 
the drug Bortezomib (Supplemental Figure 2B), another 
proteasome inhibitor. The same results were also observed 
in T47D cells (Supplemental Figure 2C). To assess if 
ESR1 is more ubiquitinated in RB1 kd MCF7 cells, we 
treated the sample with MG132, immunoprecipitated 
with an ESR1 antibody and analyzed the ubiquitin level. 
Figure 3C confirmed that ESR1 is more ubiquitinated in 
RB1 kd cells as compared to scrambled cells. A typical 
smear is observed in the stacking gel. As a consequence 
of the obtained results, we have analyzed the chaperone 
proteins involved in ESR1 protein stability [24]. In Figure 
3D, we show the co-immunoprecipitaion of ESR1 with 
HSP90. It appears that RB1 kd1 cells have less HSP90 
bound to ESR1 in untreated and MG132-treated samples 
compared to scrambled cells. The HSP90 co-chaperone, 
p23, is also reduced as expected. The level of HSP70 is 
unaltered, suggesting that pRb influences the intermediate 
complex that stabilizes the ESR1 protein [22]. Under 
basal conditions, the ESR1 is associated with chaperone 
proteins in the cytoplasm. After estradiol stimulation, 
ESR1 is shuttled to the nucleus to exert its genomic 
function on target genes [25]. The re-cycling of ESR1 on 
promoters of target genes is very fast [26], after which the 
ESR1 is exported again to the cytoplasm for proteasomal 
degradation [23]. Inhibitors of nuclear export such as 
Leptomycin B [27] or, nuclear stabilizing agents such 
as cycloheximide lead to ESR1 protein accumulation. 
When RB1 kd1 cells were treated with Leptomycin B 
(Figure 4A) or cycloheximide (Figure 4B) in combination 
with estradiol, the level of ESR1 were comparable 
with scrambled cells, confirming a cytoplasmic ESR1 
degradation driven by the proteasome pathway. 
pRb controls ESR1 protein levels in primary 
human mammary cells and Rb1 KO mice.
To assess if the mechanism takes place in a more 
physiological model, we have knocked-down RB1 in 
human mammary epithelial primary cells (HMEpC). In 
these cells, we were able to detect the short isoform of 
ESR1 [28]. In Figure 5A, we show that RB1 kd cells have 
a reduction in ESR1 levels when compared to scrambled 
Figure 3: pRb is necessary for HSP90 protein to protect ESR1 from proteasomal degradation. (A) Time course analysis of 
MCF7 cells treated with MG132 for indicated time. After 4 hours, the RB1 kd1 cells expressed the same level of ESR1 as scrambled cells. 
(B) Analysis as in (A) of three independent experiments utilizing RB1 kd1 and kd2 shRNAs. (C) MCF7 cell lysate untreated (nt) or treated 
with MG132 for 4 hours was immunoprecipitated with an ESR1 antibody and analyzed by western blot with an anti-ubiquitin antibody. The 
RB1 kd1 cells showed heavy ubiquitination that extended in the stacking gel. (D) MCF7 cell lysate untreated (nt) or treated with MG132 for 
4 hours was immunoprecipitated with ESR1 antibody. In RB1 kd1 cells, there is less HSP90 and p23 proteins bound to the ESR1 protein. 
HSP70 protein is unaltered. IgG was used as a negative control.
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cells and MG132 can rescue the phenotype as in MCF7 
and T47D cancer cell lines. To definitively demonstrate 
the role of pRb in the control of ESR1 protein levels, we 
have conditionally knocked out (KO) the Rb1 gene in the 
mouse mammary epithelium. Western blot analysis shows 
that the expression of the pRb protein is reduced by 50% 
in KO mice when compared to wild type mice (Figure 
5B,C).
DISCUSSION
Our data here show that the pRb protein plays an 
important role as an adaptor in the regulation of ESR1 
stability and functionality, a key player in hormonal 
therapy. The N-terminal domain of pRb interacts with 
the ESR1 CD domain, which is composed of the DNA 
binding domain (C) and the hinge region (D). The hinge 
region has recently been discovered to have a complex 
function. This domain contains a nuclear translocation 
signal and includes estrogen-independent regulatory 
sequences, which mediate the interaction with c-Jun and 
Sp-1 transcription factors [29]. In addition, the domain is 
modified by many posttranslational modifications [30,31] 
and together with the ligand binding domain form a surface 
for HSP90 binding which protects unliganded ESR1 from 
basal turnover [32]. We anticipate that pRb represents a 
new actor for the CD domain, which is fundamental for 
the binding of HSP90, thus regulating the fine equilibrium 
of rapid switch on/off that characterizes the activity of 
ESR1 protein. It is interesting to note that the N-terminal 
domain of pRb mediates this interaction. Although most 
of pRb’s interactions were mapped in the pocket domain, 
recently the N-terminal domain has gained much attention. 
It is involved in inhibiting the E2F transactivation ability 
[33], can interact with different proteins that control 
DNA replication [34], and form a complex with SRC-2, 
a coactivator of nuclear receptors including ESR1 [11]. 
There is a growing body of evidence that the N-terminal 
domain may have a role in tumor suppression [6,35,36] 
and our work highlights its importance in the regulation of 
ESR1 activity with a direct consequence in the response of 
breast cancer therapy.
Finally, previous papers have shown the pRb can 
act as cofactor to control the stability of different target 
proteins [6,36–38]. Interactions between pRb and the 
RIM domain of E2F1 or with PDX-1, a transcription 
factor involved in pancreas development and adult β-cell 
functions, protects these proteins from the ubiquitin-
proteasome pathway degradation [36–38]. Our model 
suggests a role for pRb as a cofactor that allows the 
interaction between HSP90 and ESR1 to form the 
chaperone intermediate complex. In the absence of pRb, 
the formation of the intermediate complex does not occur, 
thus priming the ESR1 for proteasomal degradation 
(Figure 5D). In accordance with the literature, blocking 
HSP90 function with geldanamycin disrupts the 
interaction with the ESR1 and promotes it’s degradation 
[39]. 
During tumor evolution, most hormonal-dependent 
cancers lack hormone responsiveness and dependence. 
Since steroid hormones induce differentiation, one 
explanation is that uncontrolled tumor proliferation is 
incompatible with differentiation. In this context, our 
data suggest the pRb loss, a central player of cellular 
proliferation and differentiation, dictates the steroid 
response and tumor growth. Current breast cancer therapy 
is based on a few molecular targets [40–44] and it has been 
challenging to find new candidates thus far. pRb loss can 
define a class of breast tumors that would experience little 
benefit from endocrine therapy [2,45]. Therapies that aim 
to reactivate the function of the pRb protein [9] can help 
those patients that are not responsive to hormonal therapy.
METHODS
Cells culture conditions
MCF7 and T47D breast cancer cell lines were 
purchased from American Type Culture Collection, 
Rochville, MD, USA, 293FT cell lines were from 
Invitrogen Carlsbad, CA, USA and HMEpC from Cell 
Application, San Diego, CA, USA. Cells were grown at 
Figure 4: Nuclear accumulation of ESR1 prevents 
proteasomal degradation in RB1 kd1 cells. (A) MCF7 
cells were treated with leptomycin B, estradiol or a combination 
for indicated time. Estradiol allows the translocation of ESR1 
in the nucleus and Leptomycin B prevents the nuclear export. 
After 3 or 6 hours of treatment, the RB1 kd1 cells express the 
same level of ESR1 as scrambled cells. (B) T47D cells were 
treated with CHX, estradiol, or a combination for 3 hours. CHX 
allows nuclear accumulation of ESR1. After CHX plus estradiol 
treatment, the RB1 kd1 cells express the same level of ESR1 as 
scrambled cells.
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37 0C, in a 5% CO2/95% atmosphere according to the 
manufacturer’s guidelines. Hormone-free medium was 
prepared with phenol red–free DMEM with 2 mmol/L 
L-glutamine, 0.1 mmol/L nonessential amino acids, 50 
units/mL penicillin, 50 µg/mL streptomycin, and 3% 
charcoal-stripped FBS.
Reagents
Antibodies for the following proteins: ERα (sc-
8002), ERα HC-20 (sc-543), ERα MC-20 (sc-542), pRb 
(sc-102), Hsp70 (sc-24) and Hsp90 (sc-69703) were 
purchased from Santa Cruz Biotechnology, Santa Cruz, 
CA, USA; α-tubulin (T-6074) from Sigma Inc., St Louis, 
MO, USA; P23 (MA3414) from Thermo Scientific Pierce; 
and anti-ubiquitin P4DI from Covance, Princeton, NJ, 
USA. MG-132 (10012628) from Cayman Chemical; 
Bortezomib (B-1408) and Leptomycin B (L-6100) from 
LC Laboratories; Cycloheximide (c4859) from Sigma; and 
(Z)-4-Hydroxytamoxifen from Enzo Life Sciences.
Plasmids
shRNA plasmids RB1 (TRCN0000010418, 
TRCN0000040167) were from Sigma Inc., St Louis, MO, 
USA. Scrambled shRNA (Addgene: 17920), psPAX2 
packaging plasmid (Addgene: 12260), and pMDG.2 
envelop plasmid (Addgene: 12259) were from Addgene 
Inc, Cambridge, MA, USA. ERα- His-AB, His-CD 
and His-EF plasmids were derived from VP16-ERα 
(Addgene: 11351) following amplification with primers: 
AB-BamHI-F ATG GAT CCA CCA TGA CCA TGA CCC 
TCC-3’, AB-EcoRI-Rev 5’-ATG AAT TCT CCT TGG 
CAG ATT CCA TAG-3’, CD-BamHI-F 5’-ATG GAT CCA 
CCA TGG CCA AGG AGA CTC GCT ACT GTG-3’, CD-
EcoRI-Rev 5’-ATG AAT TCT TCT TAG AGC GTT TGA 
TCA TG-3’. EF-BamHI-F 5’-ATG GAT CCA CCA TGT 
CTA AGA AGA ACA GCC TGG CC-3’, EF-EcoRI-Rev 
5’-ATG AAT TCC AGA CCG TGG CAG GGA AAC-3’. 
After BamHI/EcoRI double digestion, fragments were 
ligated into a pcDNA6 His/Myc vector. To generate the 
ERα-V5 plasmid, we have recombined the pLOVE vector 
(Addgene:15948) and the pENTR223- ERα, (DF-HCC: 
HSCD00376961) utilizing the Gateway Cloning System 
(Invitrogen). GST-Rb N-terminal (1-373 a.a.), Pocket 
(379-792a.a.) and C-terminal (793-920 a.a.) were cloned 
in PGEX-2T. All the plasmids were sequence verified.
Lentiviral production
To generate knock down cells, lentiviral particles 
were produced as described (http://www.broadinstitute.
org/genome_bio/trc/publicProtocols.html) by Rizzolio et. 
al [5]. 
Figure 5: RB1 kd primary human mammary cells and Rb1 KO mice show a reduction in ESR1 protein levels. (A) 
HMEpC RB1 kd1 cells express 50% less of the ESR1 protein compared to scrambled cells. Treatment with MG132 for 4 hours rescued 
the expression of the ESR1 protein. The quantification represents the ratio between the ESR1 and alpha-tubulin proteins and normalized 
to scrambled cells. (B) Rb1 conditional KO mice in mammary cells have a reduced expression of ESR1. (C) Quantification of 6 mice as in 
(B). (D) Working model of pRb and the chaperone complex that regulate ESR1 turnover. After the assembly of the initiation complex, pRb 
is necessary for the recruitment of the HSP90 complex that forms the intermediate complex. Without pRb, the ESR1 is more ubiquitinated 
and degraded by proteasome pathway.
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Real-time PCR
Total RNA was prepared from tissues using the RNA 
extraction kit RNAeasy (Qiagen Inc, Valencia, CA, USA). 
One μg of total RNA was reverse transcribed in a 20 μl 
reaction using M-MLV reverse transcriptase (Invitrogen, 
Carlsbad, CA, USA). Primers to amplify ER, CTDS, 
TFF1, GAPDH are the following: ESR1-for 5’ -CAT TCT 
ACA GGC CAA ATT CAG - 3’, ESR1-rev 5’ -GCA CAC 
TGC ACA GTA GCG A - 3’, CTDS-f 5’-GCT GGG AGG 
CAA AGG CTA CAA-3’ CTDS-r 5’-TCC TGC TCT GGG 
ACT CTC CT-3’, TFF1-f 5’-CCC TGG TGC TTC TAT 
CCT AAT A-3’, TFF1-r 5’-AGA AGC GTG TCT GAG 
GTG TCC-3’, GAPDH-f 5-GAA GGT GAA GGT CGG 
AGT-3’, GAPDH-r 5-CAT GGG TGG AAT CAT ATT 
GGA-3’. Quantitative Real Time PCR (qRT-PCR) was 
performed with SYBR Green PCR Master Mix (Roche 
Diagnostic, Basel, Switzerland) in a LightCycler® 480 
Real-Time PCR System instrument (Roche Diagnostic, 
Basel, Switzerland). Samples were run in triplicates and 
the efficiency of each primer was calculated utilizing an 
internal standard control [46]. All values were normalized 
for GAPDH.
Co-immunoprecipitation assay
 Sub-confluent MCF7 cells were harvested and 
proteins were prepared as follows: the cell pellet was 
resuspended in lysis buffer (20 mM Tris HCl pH 8, 137 
mM NaCl, 10% glycerol, 1% NP40, 2 mM EDTA). 3 mg 
of proteins was immunoprecipitated, utilizing 4 μg of ERα 
antibody or mouse IgG overnight at 4°C. Extracts were 
incubated with antibodies and protein A/G beads (Pierce) 
for 3 h at 4°C. Immunopellets were washed extensively 
and subjected to SDS-PAGE followed by immunoblot 
analyses to detect pRb and ERα proteins.
Immunofluorescence 
MCF7 scramble and pRb KD cells were seeded 
on cover slips and grown in hormone-free medium for 
three days. Cells were treated with 17-β-estradiol or 
ethanol (as a negative control) for 45 minutes and fixed 
in 4% paraformaldehyde, permeabilized with phosphate-
buffered saline (PBS) containing 1% Triton X-100 and 
1% bovine serum albumin, and blocked in blocking buffer 
(PBS containing 8% bovine serum albumin). Cells were 
then incubated with total ERα antibody diluted at 1:100 
(HC-20). After three washing with PBS, Alexa Fluor dyes 
(Invitrogen) were applied in blocking buffer as a secondary 
antibody. Nuclei were stained with 2’,6’-diamidino-2-
phenylindole (DAPI) in an antifade mounting medium 
(Vector laboratories, Burlingame, Calif.).
Mice
 All experiments with mice were approved by 
Temple IACUC committee. pRb floxed (FVB;129) and 
WAP-CRE (B6.Cg) mice were obtained from MMHCC 
(Mouse Models of Human Cancers Consortium). 
Mammary tissue was obtained from age-, parous- 
matched female mice, one day post-partum. Tissues were 
homogenized in Lysis Buffer (20 mM Tris HCl pH 8, 137 
mM NaCl, 10% glycerol, 1% NP40, 2 mM EDTA) and 
5-10 ug of protein extract was analysed by western blot.
Statistical analysis
 Statistical analysis was performed using GraphPad 
software by applying Student’s t-test. 
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